Pancreatic ductal adenocarcinoma (PDAC) is composed of stromal, immune, and cancerous epithelial cells. Transcriptomic analysis of the epithelial compartment allows classification into different phenotypic subtypes as classical and basal-like. However, little is known about the intra-tumor heterogeneity particularly in the epithelial...
-
September 2020 (v1)Journal articleUploaded on: April 5, 2025
-
April 2021 (v1)Journal article
Background: Although significant advances have been made recently to characterize the biology of pancreatic ductal adenocarcinoma (PDAC), more efforts are needed to improve our understanding and to face challenges related to the aggressiveness, high mortality rate and chemoresistance of this disease.Methods: In this study, we perform the...
Uploaded on: April 5, 2025 -
June 2023 (v1)Journal article
Pancreatic ductal adenocarcinoma (PDAC) has been widely studied at multiomics level. However, little isknown about its specific ubiquitination, a major post-translational modification (PTM). As PTMs regulate the final function of any gene, we decided to establish the ubiquitination profiles of 60 PDA.
Uploaded on: April 5, 2025 -
2023 (v1)Journal article
Objective Intercellular communication within pancreatic ductal adenocarcinoma (PDAC) dramatically contributes to metastatic processes. The underlying mechanisms are poorly understood, resulting in a lack of targeted therapy to counteract stromal-induced cancer cell aggressiveness. Here, we investigated whether ion channels, which remain...
Uploaded on: November 25, 2023 -
September 2024 (v1)Journal article
Background:After surgical resection of pancreatic ductal adenocarcinoma (PDAC), patients are predominantly treated with adjuvant chemotherapy, commonly consisting of gemcitabine (GEM)-based regimens or the modified FOLFIRINOX (mFFX) regimen. While mFFX regimen has been shown to be more effective than GEM-based regimens, it is also associated...
Uploaded on: January 13, 2025